abinScience | Recombinant Proteins, Antibodies & Assay Kits

Understanding Hepatitis C Virus: Structure, Pathogenesis, Vaccine Research & abinScience Tools

Discover the biology, structure, and pathogenesis of Hepatitis C Virus (HCV), including its virion structure and immune evasion strategies. Explore the latest advances in HCV vaccine development and effective tools from abinScience, such as recombinant proteins and antibodies, to support antiviral research. Updated July 30, 2025, this resource offers insights into DAA therapy and vertical transmission challenges.

Learn more

Chikungunya Virus in 2025: A Global Health Threat and the Role of Innovative Research

Discover the Chikungunya virus (CHIKV) structure, key proteins, and pathogenesis, with insights from the 2025 Foshan outbreak and global epidemiology. Learn about WHO’s warnings on CHIKV epidemic risks and explore abinScience’s advanced research tools, including recombinant proteins and antibodies, designed to support vaccine and antiviral development for this mosquito-borne disease.

Learn more

Combating Mosquito-Borne Diseases: Research Tools and Insights

Uncover the science behind mosquito-borne diseases like Chikungunya’s crippling joint pain, Dengue’s complex serotypes, West Nile’s neurological risks, Yellow Fever’s historic threat, Zika’s congenital dangers, and Japanese Encephalitis’s brain inflammation. Learn about the challenges of controlling these viruses and explore cutting-edge lab tools for diagnostics, vaccine development, and research. abinScience offers specialized antibodies and recombinant proteins to target viral proteins, empowering scientists to fight these global health threats effectively.

Learn more

COVID-19 Resurgence in 2025: Omicron NB.1.8.1 Drives Surge with Enhanced Immune Escape

Since April 2025, China has faced a resurgence of COVID-19, with positivity rates in outpatient and inpatient settings rising sharply from 7.5% to 16.2% and 3.3% to 6.3%, respectively. Southern provinces report higher infection rates than the north, with the Omicron NB.1.8.1 variant driving the surge due to its enhanced immune escape capabilities. Symptoms remain mild, including sore throat, low-grade fever, and cough. The pandemic is expected to peak in late May and subside by late June. abinScience offers high-quality SARS-CoV-2-related proteins and antibodies to support cutting-edge virology research.

Learn more

InVivoMAb™ Plus: Precision In Vivo Antibodies for Animal Models by abinScience

The abinScience InVivoMAb™ Plus series offers over 400 high-quality in vivo antibodies, validated for purity, specificity, and functionality, ideal for research in cancer, autoimmune diseases, and infectious diseases. This page details the activity validation experiments and ELISA tests of anti-PD-1 and anti-PD-L1 antibodies in mouse models (B16-F10 and CT26), demonstrating significant tumor suppression and antigen-binding capabilities. The product list includes a range of antibodies and isotype controls designed for immune regulation and tumor immunotherapy, supported by batch stability and traceability.

Learn more

Science Discovery: The Role of Erythropoietin (EPO) in Tumor Immune Evasion

Recent research has uncovered a critical role for erythropoietin (EPO) in tumor immune evasion. Tumor cells secrete EPO, which, through the EPOR signaling pathway, suppresses the immune function of macrophages, aiding tumors in escaping immune surveillance. Blocking the EPO/EPOR signaling enhances the efficacy of PD-1 immunotherapy, offering a novel strategy for cancer treatment.

Learn more

Tuberculosis Research and Scientific Applications in 2025: Advances in Diagnosis, Treatment, and Vaccines

This schematic illustration highlights four key research areas in tuberculosis (TB) studies: ESAT-6/CFP-10 as core antigens for immunodiagnostic platforms (IGRA, ELISPOT), HspX as a biomarker for latent infection and stress response, KatG and InhA as primary targets for drug resistance mechanism analysis, and Ag85 series antigens for vaccine target validation. Designed for scientific publications, this figure supports research in TB diagnostics, immune mechanisms, and drug resistance studies.

Learn more

Unveiling the WHO-Prioritized Nipah Virus: Deadly Bat-Borne Pathogen Uncovered

This article provides a comprehensive overview of the Nipah virus (NiV), a highly lethal bat-borne pathogen causing severe respiratory and neurological diseases. It explores NiV’s global distribution, viral structure, protein functions, pathogenesis mechanisms, and epidemiological history, highlighting outbreaks in India and Bangladesh. Recent research progress, including vaccine and antibody developments, is discussed, alongside key research targets like the G protein and Ephrin-B2/B3 receptors. abinScience offers specialized proteins and antibodies to support NiV research, empowering scientists in their pursuit of solutions against this priority pathogen.

Learn more

JAK2 V617F Mutation and Its Role in Coronary Plaque Erosion

This study, published in European Heart Journal, investigates the JAK2 V617F mutation’s association with coronary plaque erosion, revealing a significant link (over 10-fold increased risk). Using digital droplet PCR and single-cell RNA sequencing, it demonstrates that JAK2 V617F enhances neutrophil activation and NETosis, driving plaque erosion. These findings provide a basis for precise cardiovascular risk stratification and support targeted JAK2 therapies.

Learn more

Rabies Outbreak in Timor-Leste: Mechanisms, Prevention, and Research Solutions

In May and June 2025, Timor-Leste reported four fatal rabies cases, prompting the World Health Organization to classify the national public health risk as high. This article explores the rabies virus (RABV), its deadly mechanisms, and the critical role of post-exposure prophylaxis (PEP) in prevention. It details the virus’s key proteins, transmission cycle, and immune evasion strategies, alongside advancements like mRNA vaccines and the Milwaukee Protocol’s limited success. abinScience’s RABV-related research products are highlighted as vital tools for studying this lethal zoonotic disease.

Learn more

Novel Dual-Target Bimagrumab and Semaglutide Achieve Fat Loss Without Muscle Loss

The BELIEVE IIb phase study, presented at the 2025 ADA Annual Meeting, demonstrates that the combination of Semaglutide and Bimagrumab significantly enhances fat loss while preserving muscle mass in overweight and obese individuals. With 92.8% of weight loss attributed to fat and an average waist reduction of 21 cm, this dual-target therapy, acting on GLP-1 and ActRII pathways, offers superior body composition improvement and long-term metabolic benefits compared to monotherapy. abinScience provides high-quality research reagents for these targets to support further scientific advancements.

Learn more

Unveiling the First Step of Viral Fusion: Scientists Capture Early Fusion Intermediate of ACE2-Mediated Coronavirus

Fudan University’s study in Cell unveils the early fusion intermediate (E-FIC) structure of SARS-CoV-2 Spike protein with ACE2, identifying HR1 exposure as a key step in membrane fusion. They developed ALSE, an HR1-targeting inhibitor, showing potent antiviral activity and safety in vitro and in animal models, offering a novel target and structural basis for anti-coronavirus drug development.

Learn more

Recombinant Proteins

Antibodies

Assay Kits

Browse by products

Featured content

About abinScience

News

Quick access

Contact us